Analysis Note
Single main spot with additional trace spot by TLC
Biochem/physiol Actions
Cell permeable: no
Reversible: yes
Primary Targetcaspase-3, caspase-7
Product does not compete with ATP.
Target IC50: 3.2 nM and 22.6 nM, against caspases-3 and -7, respectively
General description
A tetrapeptidyl aldehyde that acts as a potent, reversible and active site binding inhibitor of caspases-3 and -7 (IC50 = 3.2 nM and 22.6 nM, respectively) and displays ~100-fold greater selectivity over caspases-8 and -9 (IC50 = 577.6 nM and 364.7 nM, respectively). Offers protection against Camptothecin (Cat. No. 208925), and anti-Fas-mediated apoptosis in Jurkat T cells.
A tetrapeptidyl aldehyde that acts as a potent, reversible and active site binding inhibitor of caspases-3 and -7 (IC50 = 3.2 nM and 22.6 nM, respectively) and displays ~100-fold greater selectivity over caspases-8 and -9 (IC50 = 577.6 nM and 364.7 nM, respectively). Offers protection against Camptothecin (Cat. No. 208925), and anti-Fas-mediated apoptosis in Jurkat T cells.r>Note: aldehyde-based inhibitors are less cell-permeable than FMK-based inhibitors, so higher concentrations may be required for cell-based inhibition studies (e.g. 100 µM).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Yoshimori, A., et al. 2004. BMC Pharmacol.4, 7.
Packaging
1 mg in Plastic ampoule
Packaged under inert gas
Sequence
Ac-Asp-Asn-Leu-Asp-CHO
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: